Xencor (XNCR) Doses First Patient In Myeloid Leukemia Trial
Zacks Investment Research | Sep 13, 2016 01:36AM ET
Xencor, Inc. (NASDAQ:XNCR) announced that the first patient has been dosed in a phase I trial on lead candidate XmAb14045 for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.
The trial will evaluate the safety and tolerability of weekly intravenous administration of XmAb14045 and determine the maximally tolerated dose/dosing schedule. The trial will enrol approximately 60 patients with AML or other CD123-expressing hematologic malignancies who will receive XmAb14045.
The candidate showed efficacy and potent depletion of target cells in primate studies from a well-tolerated single IV dose.
We note that XmAb14045 is Xencor's lead bispecific candidate. The company earlier inked a collaboration agreement with Swiss major Novartis (NYSE:NVS) .
As per the agreement terms, the companies will collaborate to develop and commercialize two pipeline candidates – XmAb14045 and XmAb13676 (to enter clinical development for B-cell malignancies in 2016). The companies will share the cost of the development of the candidates. While Xencor will retain commercialization rights in the U.S., Novartis will own the marketing rights in the rest of the world.
Additionally, Novartis will receive worldwide rights to Xencor's bispecific technology to develop and commercialize four targets. These targets will be selected by Novartis and Xencor may elect to co-detail one of these targets in the U.S. Novartis will also receive a worldwide non-exclusive license to use Xencor's XmAb Fc technologies in up to 10 molecules.Xencor currently carries a Zacks Rank #3 (Hold). A couple of well placed stocks in the healthcare stocks include Pacira Pharmaceuticals (NASDAQ:PCRX) and ANI Pharmaceuticals (NASDAQ:ANIP) . Both these stocks sport a Zacks Rank #1 (Strong Buy).
You can see Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.